Wall Street Analysts Are Bullish on Top Healthcare Picks

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Mylan Inc (NASDAQ: MYL) and Strongbridge Biopharma Plc (NASDAQ: SBBP) with bullish sentiments.

Mylan Inc (NASDAQ: MYL)

Guggenheim analyst Rohit Vanjani maintained a Buy rating on Mylan Inc (NASDAQ: MYL) today and set a price target of $59. The company’s shares opened today at $36.69.

Vanjani wrote:

“We maintain our BUY rating. 1Q18 Revenue of ~$2,685M was in line with our forecast but below consensus of ~$2,730M. With respect to the segments, N. American revenue of ~$985M (down ~19% y/y) was below Street estimates of ~$1,100M, but was offset by European revenues of ~$1,038M (up ~16% y/y), above consensus of ~$967M. European strength was driven by double-digit y/y growth in core markets such as and Poland. Adj. EPS of $0.96 was slightly higher than our/Street estimates of $0.93/$0.95. We note that management had already set expectations for the 1Q18 results at the last earnings call and then again at the April Investor Day, noting that 1Q18 EPS would amount to ~17% of total EPS (vs. ~20% in 1Q17). Given that MYL reaffirmed 2018 guidance, the 1Q18 EPS equals ~17.8% of the midpoint of the EPS guidance ($5.20-$5.60).”

According to TipRanks.com, Vanjani is a 4-star analyst with an average return of 10.6% and a 50.0% success rate. Vanjani covers the Healthcare sector, focusing on stocks such as Sienna Biopharmaceuticals Inc, Revance Therapeutics, and Endo International.

Currently, the analyst consensus on Mylan Inc is Moderate Buy and the average price target is $50.56, representing a 37.8% upside.

In a report released yesterday, Mizuho Securities also reiterated a Buy rating on the stock with a $51 price target.

See today’s analyst top recommended stocks >>

Strongbridge Biopharma Plc (NASDAQ: SBBP)

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating on Strongbridge Biopharma Plc (NASDAQ: SBBP) today and set a price target of $14. The company’s shares opened today at $8.15.

Piros said:

“SONICS Remains Focus. Based on the strong scientific validation behind RECORLEV’s potential in Cushing’s syndrome, we anticipate investors focus to remain on RECORLEV’s safety profile. As the more potent (and potentially safer) enantiomer within ketoconazole, RECORLEV could demonstrate a favorable safety profile over the racemic mixture, in our view. What we believe may not be appreciated is the potential for a wider therapeutic index to achieve more clinically meaningful improvement across not just urinary free cortisol, but also secondary measures such as those associated with cardiovascular risk factors.”

According to TipRanks.com, Piros has currently no stars on a ranking scale of 0-5 stars, with an average return of -3.6% and a 46.3% success rate. Piros covers the Healthcare sector, focusing on stocks such as Spring Bank Pharmaceuticals Inc, Global Blood Therapeutics, and Bellicum Pharmaceuticals.

Strongbridge Biopharma Plc has an analyst consensus of Strong Buy, with a price target consensus of $14.67.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.